We’re pleased to share that Leyden Labs CEO Koenraad Wiedhaup will present at the 41st Annual J.P. Morgan Healthcare Conference.
Recently, our article entitled “The influenza hemagglutinin stem antibody CR9114: Evidence for a narrow evolutionary path towards universal protection,” appeared in a special issue of Frontiers in Virology on the role of genetic and structural insights of neutralizing antibodies to guide viral vaccine design.
A new research article by Leyden Labs and partners at Imperial College has been published in Infectious Diseases & Therapy.
Leyden Labs announces a $140M Series B financing led by Casdin Capital and GV (formerly Google Ventures) with participation from leading global life science investors. The proceeds accelerate development of products against a broad range of respiratory viruses through mucosal protection.
Janssen’s CR9114 is a human monoclonal antibody that protects against influenza A & B. This exclusive license supports Leyden Labs’ mission to optimize mucosal protection against entire viral families to prevent future pandemics.
HollandBIO represents and connects life science companies in the Netherlands and stimulates rapid accessibility of innovation. Over 200 companies are linked through this organization to work towards a better future. Recently, Leyden Labs has also become a member.
Earlier this month Labiotech.eu published a Top 15 of Biotech Companies in Amsterdam. They have specifically put together a list of companies seeking to change the world. We are very proud to share this list with some of the biggest names in the Biotech Industry and several companies that have left the start-up phase years ago.
InvestInHolland points out the vital role of the Netherlands in today’s global health system by going through the past, present and future of the Dutch pharmaceutical industry. They name Leyden Labs as an example of the future of pharmaceutical development and specifically highlight our mission to protect against many viruses at once.
Matthew Pillar interviews our CEO, Koenraad Wiedhaup, looking back at when Leyden Labs was founded, Koenraad's unique background and looking ahead to how our products can be complementary to vaccines.
In the Empowered Patient Podcast Karen Jacoda highlights latest innovations in healthcare, pharma and biotech and changing dynamics between patients and physicians in her podcast. For this episode, Karen interviewed our CEO Koenraad, who spoke about Leyden Labs' proactive approach toward viral threats.
To read the full press release, click below.
Leyden Labs was covered as Emerging Company Profile by Scrip. Sten Stovall discusses in his article how our novel intranasal medicine can potentially target viral families to prevent the next pandemic.
Last month, our CEO Koenraad Wiedhaup spoke with co-founder and editor of MedNous, Victoria English, about Leyden Labs. They discussed the development of our platform and portfolio of prophylactic nasal sprays and their potential role to prevent future pandemics.
Victor Kotsev has evaluated a broad range of initiatives following the COVID-19 pandemic. He also highlights Leyden Labs' proactive approach toward viral diseases amongst a range of vaccine and treatment options.
Heather McKenzie recently wrote an article about pandemic preparedness. She explores future threats and a collection of measures to protect against future outbreaks. You can read the full article on the BioSpace website.
Learn more about our story in the conversation between Koenraad Wiedhaup (CEO) and David Schenkein (General Partner at GV and board member at Leyden Labs). They discuss the mission and approach, investment round, fantastic team and plans for the future.
The passing of John Martin, who served as a member of our Supervisory Board came unexpectedly and has left us with great sadness. Our thoughts are with his family and his friends.
Cormac Sheridan wrote an article about our investment round with GV (formerly Google Ventures), F-Prime, Casdin Capital and Brook Byers. To learn more about our Series A and our story, visit the BioWorld website.
Leading up to the public launch, our CEO Koenraad Wiedhaup spoke with Amber Tong of Endpoints News about Leyden Labs. An interesting read to learn more about our mission to free humanity from the burden of respiratory viruses.
Funding to advance platform and portfolio of intranasal products that protect against a broad range of respiratory viruses, including influenza and coronaviruses, to let people live their lives freely
Leyden Laboratories B.V.
2333 BD Leiden
Leyden Laboratories Co.
191 Dexter Avenue
Leyden Labs S.L.
Avda. del Conocimiento 41.A210
Centro de Empresas
Parque Tecnológico de la Salud